二氧化碳作为EVAR对比剂对肾脏的益处:1年结局新视角
该回顾性研究纳入博洛尼亚Sant'Orsola医院接受EVAR的患者,比较二氧化碳联合低剂量碘对比剂与标准碘对比剂对肾功能的影响。结果显示CO2组术后即刻eGFR轻度改善,而标准碘对比剂组显著恶化,1年时碘对比剂组肾功能下降更明显。作者认为CO2方案更安全,可降低对比剂后急性肾损伤发生率。
要点
- CO2联合低剂量碘对比剂组术后即刻eGFR平均变化+5.10%±3.2,标准碘对比剂组为-9.65%±4。
- 对比剂后急性肾损伤发生率CO2组9% vs 对照组27%。
- 12个月时碘对比剂组eGFR平均下降-19.2%±11.1,CO2组为-7.40%±3.5。
核心结论
- 单独使用CO2或联合低剂量碘对比剂较全剂量碘对比剂更安全,可降低EVAR患者对比剂后急性肾损伤发生率。
- 研究意外发现标准剂量碘对比剂组在1年随访时肾功能显著恶化,提示碘对比剂所致急性肾损伤可能引发慢性损伤过程并影响长期肾脏结局。
研究设计与样本
- 回顾性研究,回顾博洛尼亚Sant'Orsola医院血管外科接受EVAR患者的资料。
- 在干预前、术后即刻和12个月评估估算肾小球滤过率(eGFR)。
主要发现
- 术后即刻CO2组eGFR平均变化+5.10%±3.2,对照组平均变化-9.65%±4。
- 对比剂后急性肾损伤发生率CO2组9% vs 对照组27%。
- 12个月时CO2组eGFR平均下降-7.40%±3.5,对照组平均下降-19.2%±11.1。
临床怎么用
- 作者认为,研究结果可指导临床医生和外科医生在选择手术方式时不仅考虑碘对比剂对肾功能的即刻影响,还应考虑其潜在长期影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Endovascular aneurism repair (EVAR) is a minimally invasive alternative to open surgery for the treatment of abdominal aortic aneurysm. Iodine contrast medium (ICM) is considered the gold standard, at the high price of related nephrotoxicity and allergic reactions. Carbon dioxide (CO2) has been suggested as an alternative non-nephrotoxic contrast media agent. We aimed to evaluate the safety and the renal impact of the administration of CO2, compared with ICM in EVAR procedures. DESIGN, SETTING, PARTICIPANTS, AND MEASUREMENTS: We retrospectively reviewed data of patients who underwent EVAR at the Vascular Surgery Department of the Sant'Orsola Hospital in Bologna. Estimated glomerular filtration rate (eGFR) was evaluated before intervention, immediately after and at 12 months. RESULTS: In total, 22 patients received CO2 and low-dose ICM (CO2 Group) and 22 received standard ICM (Control Group), matched for clinical characteristics and renal function at the time of procedure. Pre and post-operative renal function values (eGFR) were compared between the two groups: in the immediate post-operative the group treated with CO2 and low-dose ICM globally showed a slight improvement in renal function (mean eGFR +5.10%±3.2), meanwhile the group treated with standard dose of ICM presented a significant worsening of renal function compared with pre-procedure values (mean eGFR -9.65%±4). Incidence of post-contrast acute kidney injury (PC-AKI) was 9% in the CO2 group vs 27% in the Control group. At 12 months, the renal impairment was significantly greater in the ICM group than in the CO2 group (mean eGFR decrease -19.2%±11.1 and -7.40%±3.5, respectively). CONCLUSIONS: Administration of either CO2 alone or along with low-dose ICM showed to be safer than full-dose ICM alone, lowering the incidence of PC-AKI in patients undergoing EVAR. Unexpectedly, our study revealed also a significant worsening of renal function in patients treated with standard dose of ICM in 1-year follow-up, introducing the concept that acute renal damage caused by ICM could elicit a chronic injury process that affect long-term renal outcomes. CLINICAL IMPACT: Evaluating the safety and the renal impact of the administration of CO2, compared to Iodinate Contrast Medium, in EVAR procedures represents a first step in order to further tayloring medical procedures on patients characteristics. Our findings can guide the clinicians and surgeons in the procedures choice, not considering only the immediate effect of ICM on renal function but also the potential long-term effects.
引用
- Busutti M, Sensoni A, Vacirca A, et al. Renal Benefits of CO2 as a Contrast Media for EVAR Procedures: New Perspectives on 1 Year Outcomes. J Endovasc Ther. 2023. PMID: 37070632. doi:10.1177/15266028231162258
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。